

a one-time extension of the allowed outage time for an emergency diesel generator from 14 days to 30 days.

Date of issuance: July 26, 2019.

Effective date: As of the date of issuance and shall be implemented immediately.

Amendment No.: 248. A publicly-available version is in ADAMS under Accession No. ML19203A166; documents related to this amendment are listed in the Safety Evaluation enclosed with the amendment.

Renewed Facility Operating License No. DPR-67: The amendment revised the Renewed Facility Operating License and Technical Specifications.

Public comments requested as to proposed no significant hazards consideration (NSHC): Yes. The notice appeared on July 23, 2019, and July 24, 2019, in the *Treasure Coast Newspapers*, St. Lucie County, Florida. The notice provided an opportunity to submit comments on the Commission's proposed NSHC determination. No comments were received.

By letter dated July 24, 2019, the licensee supplemented its license amendment request dated July 19, 2019, to request the deferral of certain surveillance requirements on the remaining emergency diesel generators until after the completion of the proposed extended allowed outage time. By letter dated July 25, 2019, the licensee withdrew its request to defer performance of the surveillance requirements based on the current repair schedule for the inoperable emergency diesel generator. The licensee stated that its July 25, 2019, letter replaced the July 24, 2019, letter in its entirety. As a result, the NRC staff only reviewed the changes requested in the licensee's July 19, 2019, request, as supplemented by the licensee's letter dated July 25, 2019.

The Commission's related evaluation of the amendment, finding of exigent circumstances, State consultation, and final NSHC determination are contained in a Safety Evaluation dated July 26, 2019.

Attorney for licensee: Debbie Hendell, Managing Attorney—Nuclear, Florida Power & Light, 700 Universe Blvd., MS LAW/JB, Juno Beach, FL 33408-0420.

NRC Branch Chief: Undine Shoop.

Tennessee Valley Authority, Docket No. 50-328, Sequoyah Nuclear Plant (Sequoyah), Unit 2, Hamilton County, Tennessee

Date of amendment request: July 14, 2019.

Description of amendment: The amendment approved a one-time change to Sequoyah, Unit 2, Technical

Specification Table 3.3.3-1, "Post Accident Monitoring Instrumentation," Function 15c, to permit the reactor vessel level instrumentation system (RVLIS) upper range level channels to not be operable for the remainder of Operating Cycle 23 under certain compensatory actions. Sequoyah, Unit 2, is scheduled to start the Cycle 23 refueling outage in Spring 2020.

The licensee also added License Condition 2.C.(26) to the Renewed Facility Operating License to implement the compensatory measures described in Section 3.8, "Additional Compensatory Measures," of the enclosure during the timeframe the RVLIS upper range level channels are not required to be operable for the remainder of Cycle 23. If the RVLIS upper range level channels are returned to operable status prior to the end of Cycle 23, then these compensatory measures will no longer be required.

Date of issuance: July 18, 2019.

Effective date: As of the date of issuance and shall be implemented immediately.

Amendment No.: 338. A publicly-available version is in ADAMS under Accession No. ML19196A221; documents related to this amendment are listed in the Safety Evaluation enclosed with the amendment.

Renewed Facility Operating License DPR-79: The amendment revised the Renewed Facility Operating License and Technical Specifications.

Public comments requested as to proposed no significant hazards consideration (NSHC): Yes. The notice appeared on July 17, 2019, in the *Chattanooga Times Free Press*, Hamilton County, Tennessee. The notice provided an opportunity to submit comments on the Commission's proposed NSHC determination. No comments have been received.

The Commission's related evaluation of the amendment, finding of exigent circumstances, State consultation, and final NSHC determination are contained in a Safety Evaluation dated July 18, 2019.

Attorney for licensee: General Counsel, Tennessee Valley Authority, 400 West Summit Hill Drive, 6A West Tower, Knoxville, TN 37902.

NRC Branch Chief: Undine Shoop.

Dated at Rockville, Maryland, this 6th day of August, 2019.

For the Nuclear Regulatory Commission.

Blake D. Welling,

Deputy Director, Division of Operating Reactor Licensing, Office of Nuclear Reactor Regulation.

[FR Doc. 2019-17160 Filed 8-12-19; 8:45 am]

BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

[NRC-2019-0001]

Sunshine Act Meetings

TIME AND DATE: Weeks of August 12, 19, 26, September 2, 9, 16, 2019.

PLACE: Commissioners' Conference Room, 11555 Rockville Pike, Rockville, Maryland.

STATUS: Public and Closed.

MATTERS TO BE CONSIDERED:

Week of August 12, 2019

Wednesday, August 14, 2019

9:00 a.m. Hearing on Early Site Permit for the Clinch River Nuclear Site: Section 189a. of the Atomic Energy Act Proceeding (Public Meeting). (Contact: Mallecia Sutton: 301-415-0673)

This hearing will be webcast live at the Web address—<http://www.nrc.gov/>.

Week of August 19, 2019—Tentative

There are no meetings scheduled for the week of August 19, 2019.

Week of August 26, 2019—Tentative

There are no meetings scheduled for the week of August 26, 2019.

Week of September 9, 2019—Tentative

Monday, September 9, 2019

10:00 a.m. NRC All Employees Meeting (Public Meeting). Marriott Bethesda North Hotel, 5701 Marinelli Road, Rockville, MD 20852

Tuesday, September 10, 2019

10:00 a.m. Briefing on NRC International Activities (Closed—Ex. 1 & 9)

Week of September 16, 2019—Tentative

There are no meetings scheduled for the week of September 16, 2019.

CONTACT PERSON FOR MORE INFORMATION:

For more information or to verify the status of meetings, contact Denise McGovern at 301-415-0681 or via email at Denise.McGovern@nrc.gov. The schedule for Commission meetings is subject to change on short notice.

The NRC Commission Meeting Schedule can be found on the internet at: <http://www.nrc.gov/public-involve/public-meetings/schedule.html>.

The NRC provides reasonable accommodation to individuals with disabilities where appropriate. If you need a reasonable accommodation to participate in these public meetings or need this meeting notice or the transcript or other information from the public meetings in another format (e.g.,

braille, large print), please notify Kimberly Meyer-Chambers, NRC Disability Program Manager, at 301-287-0739, by videophone at 240-428-3217, or by email at Kimberly.Meyer-Chambers@nrc.gov. Determinations on requests for reasonable accommodation will be made on a case-by-case basis.

Members of the public may request to receive this information electronically. If you would like to be added to the distribution, please contact the Nuclear Regulatory Commission, Office of the Secretary, Washington, DC 20555 (301-415-1969), or by email at Wendy.Moore@nrc.gov or Tyesha.Bush@nrc.gov.

The NRC is holding the meetings under the authority of the Government in the Sunshine Act, 5 U.S.C. 552b.

Dated at Rockville, Maryland, this 8th day of August, 2019.

For the Nuclear Regulatory Commission.

Denise L. McGovern,

Policy Coordinator, Office of the Secretary.

[FR Doc. 2019-17378 Filed 8-9-19; 11:15 am]

BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on the Medical Uses of Isotopes: Meeting Notice

AGENCY: U.S. Nuclear Regulatory Commission.

ACTION: Notice of meeting.

The U.S. Nuclear Regulatory Commission (NRC) will convene a meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on September 10-11, 2019. A sample of agenda items to be discussed during the public session includes: (1) An update on medical-related events; (2) a discussion of the ACMUI's recommendations and comments on the draft Xcision® GammaPod Licensing Guidance; (3) a discussion on the status of emerging technologies licensed under Title 10 *Code of Federal Regulations* (10 CFR) Part 35.1000; (4) a discussion of the ACMUI's recommendations related to the appropriateness of the required medical event reporting in accordance with 10 CFR 35.3045; (5) a presentation from the National Nuclear Security Administration on their initiative to reduce the use of radioactive materials; (6) a discussion of the ACMUI's recommendations for improving the ACMUI's institutional memory; (7) a discussion of the ACMUI's recommendations and comments regarding the NRC's policy decision related to infiltrations and medical event reporting; (8) an update on the

NRC staff's evaluation of training and experience requirements for radiopharmaceuticals requiring a written directive; and (9) a discussion on the U.S. Pharmacopeia General Chapter <825>. *The agenda is subject to change.* The current agenda and any updates will be available at <http://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2019.html> or by emailing Ms. Kellee Jamerson at the contact information below.

Purpose: Discuss issues related to 10 CFR part 35 Medical Use of Byproduct Material.

Date and Time for Open Sessions: September 10, 2019, from 8:30 a.m. to 2:45 p.m. and September 11, 2019, from 8:30 a.m. to 11:30 a.m. Eastern Standard Time (EST).

Date and Time for Closed Session: September 10, 2019, from 7:30 a.m. to 8:30 a.m. and 2:45 p.m. to 5:00 p.m. EST. These sessions will be closed on September 10, 2019, for badging and enrollment of new members to the ACMUI and for required annual training, respectively.

Address for Public Meeting: U.S. Nuclear Regulatory Commission, Two White Flint North Building, Room T-2D30, 11545 Rockville Pike, Rockville, Maryland 20852.

Public Participation: Any member of the public who wishes to participate in the meeting in person or via phone should contact Ms. Jamerson using the information below. The meeting will also be webcast live at <https://video.nrc.gov/>.

Contact Information: Ms. Kellee Jamerson, email: Kellee.Jamerson@nrc.gov, telephone: (301) 415-7408.

Conduct of the Meeting

Christopher J. Palestro, M.D. will chair the meeting. Dr. Palestro will conduct the meeting in a manner that will facilitate the orderly conduct of business. The following procedures apply to public participation in the meeting:

1. Persons who wish to provide a written statement should submit an electronic copy to Ms. Jamerson using the contact information listed above. All submittals must be received by September 5, 2019, three business days before the meeting, and must pertain to the topics on the agenda for the meeting.

2. Questions and comments from members of the public will be permitted during the meeting, at the discretion of the Chairman.

3. The draft transcript and meeting summary will be available on ACMUI's website <http://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2019.html> on or about October 25, 2019.

4. Persons who require special services, such as those for the hearing impaired, should notify Ms. Jamerson of their planned attendance.

This meeting will be held in accordance with the Atomic Energy Act of 1954, as amended (primarily Section 161a); the Federal Advisory Committee Act (5 U.S.C. App); and the Commission's regulations in Title 10 of the *Code of Federal Regulations*, Part 7.

Dated at Rockville, Maryland, this 8th day of August 2019.

For the U.S. Nuclear Regulatory Commission.

Russell E. Chazell,

Federal Advisory Committee Management Officer.

[FR Doc. 2019-17267 Filed 8-12-19; 8:45 am]

BILLING CODE 7590-01-P

OVERSEAS PRIVATE INVESTMENT CORPORATION

Sunshine Notice—September 4, 2019 Public Hearing

TIME AND DATE: 1:00 p.m., Wednesday, September 4, 2019.

PLACE: Offices of the Corporation, Twelfth Floor Board Room, 1100 New York Avenue NW, Washington, DC.

STATUS: Hearing OPEN to the Public at 1:00 p.m.

MATTERS TO BE CONSIDERED: This will be a Public Hearing, held in conjunction with each meeting of OPIC's Board of Directors, to afford an opportunity for any person to present views regarding the activities of the Corporation.

Individuals wishing to address the hearing orally must provide advance notice to OPIC's Corporate Secretary no later than 5 p.m., Tuesday, August 27, 2019. The notice must include the individual's name, title, organization, address, and telephone number, and a concise summary of the subject matter to be presented.

Oral presentations may not exceed ten (10) minutes. The time for individual presentations may be reduced proportionately, if necessary, to afford all participants who have submitted a timely request an opportunity to be heard.

Participants wishing to submit a written statement for the record must submit a copy of such statement to OPIC's Corporate Secretary no later than 5 p.m. Tuesday, August 27, 2019. Such statement must be typewritten, double spaced, and may not exceed twenty-five (25) pages.

Upon receipt of the required notice, OPIC will prepare an agenda, which will be available at the hearing, that